What Is SIFO?

Small Intestinal Fungal Overgrowth (SIFO) is a condition in which fungi — primarily Candida species — proliferate excessively in the small intestine. While Candida is a normal commensal organism in the human gut (present in 40-80% of healthy individuals), overgrowth occurs when the ecological balance shifts in favour of fungal proliferation.

SIFO was first formally characterised in a 2015 study by Dr. Satish Rao at Augusta University, which found that 25.3% of patients with unexplained GI symptoms had SIFO, confirmed by duodenal aspiration and culture. This study brought attention to a condition that had been largely overlooked in conventional gastroenterology.

Risk Factors for Candida Overgrowth

Several factors predispose to fungal overgrowth in the gut:

  • Antibiotic use — antibiotics eliminate competing bacterial populations, creating ecological niches for Candida to fill
  • Proton pump inhibitor (PPI) use — reduced stomach acid allows more fungi to survive transit to the small intestine
  • High-sugar diet — Candida thrives on simple sugars; a diet high in refined carbohydrates promotes fungal growth
  • Immunosuppressive therapy — corticosteroids and other immunosuppressants reduce antifungal immune surveillance
  • Diabetes and insulin resistance — elevated blood glucose provides substrate for Candida and impairs immune function
  • Hormonal contraceptives — oestrogen promotes Candida adhesion to mucosal surfaces

Symptoms of Candida Overgrowth and SIFO

SIFO symptoms overlap significantly with SIBO, making clinical differentiation challenging:

Digestive Symptoms

  • Bloating and abdominal distension (the most common complaint)
  • Nausea and belching
  • Diarrhoea, constipation, or alternating bowel patterns
  • Gas and flatulence
  • Abdominal pain, often diffuse rather than localised

Systemic Symptoms

Candida overgrowth can produce systemic symptoms through several mechanisms: direct immune activation, production of toxic metabolites (acetaldehyde, gliotoxin), and increased intestinal permeability:

  • Brain fog and cognitive dysfunction — acetaldehyde produced by Candida is neurotoxic and can impair cognitive function
  • Fatigue — both from immune activation and from impaired nutrient absorption
  • Sugar and carbohydrate cravings — Candida metabolites may influence host food preferences to favour their own growth substrates
  • Skin manifestations — fungal acne, chronic nail infections, intertrigo (skin fold infections), and recurrent vaginal yeast infections
  • Joint pain — Candida-derived antigens can trigger inflammatory joint symptoms
  • Mood disturbances — anxiety and depression have been associated with Candida overgrowth in observational studies
A key clinical clue for SIFO vs SIBO: patients with SIFO often report that their symptoms worsened after antibiotic use (which killed competing bacteria) and that sugar dramatically exacerbates their symptoms. Recurrent vaginal yeast infections or oral thrush suggest systemic Candida overgrowth.

Testing for SIFO

Diagnosing SIFO is more challenging than diagnosing SIBO:

  • Upper endoscopy with duodenal aspirate and culture — the gold standard; fungal growth above 1000 CFU/mL confirms SIFO
  • Organic Acids Test (OAT) — urinary markers including D-arabinitol and citramalic acid can suggest Candida overgrowth, though this is an indirect measure
  • Comprehensive stool analysis — can identify Candida species in the stool, though this reflects colonic rather than small intestinal fungal populations
  • Blood antibodies (IgG, IgA, IgM anti-Candida) — elevated levels suggest systemic immune response to Candida, though interpretation requires clinical context

Treatment Approaches

Pharmaceutical Antifungals

First-line pharmaceutical treatment typically involves fluconazole (100-200mg daily for 2-3 weeks) or nystatin (500,000 units three times daily for 2-4 weeks). Nystatin is not absorbed systemically, making it suitable for gut-limited overgrowth with minimal systemic side effects.

Herbal Antifungals

Several botanical agents have demonstrated antifungal activity:

  • Caprylic acid — a medium-chain fatty acid from coconut oil with demonstrated anti-Candida activity; 500-1000mg three times daily
  • Oregano oil — carvacrol has potent antifungal properties; 200mg enteric-coated capsules two to three times daily
  • Berberine — inhibits Candida biofilm formation and has direct fungicidal activity; 500mg two to three times daily
  • Undecylenic acid — a fatty acid with specific anti-Candida activity; often used in combination with other agents
  • Saccharomyces boulardii — this probiotic yeast directly competes with Candida for adhesion sites and produces antimicrobial compounds

Dietary Modifications

During antifungal treatment, dietary modifications reduce the substrate available for Candida growth:

  • Eliminate refined sugar, high-fructose corn syrup, and fruit juice
  • Reduce total carbohydrate intake, particularly refined grains
  • Limit alcohol (which is metabolised similarly to sugar and promotes Candida)
  • Increase healthy fats and quality protein to maintain calories
  • Include natural antifungal foods: coconut oil, garlic, ginger, and apple cider vinegar

Preventing Recurrence

SIFO often coexists with SIBO and may recur if underlying factors are not addressed:

  • Restore bacterial diversity with diverse prebiotic fibres and fermented foods after antifungal treatment
  • Address any ongoing PPI use if possible, as acid suppression is a major risk factor for recurrence
  • Manage blood sugar and insulin resistance through diet and exercise
  • Support immune function through adequate sleep, stress management, and nutrient repletion

GutIQ's comprehensive assessment evaluates symptom patterns that may suggest fungal overgrowth alongside bacterial issues, helping you and your practitioner determine the most appropriate testing and treatment strategy.